மூலதனம் வாழ்க்கை அறிவியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மூலதனம் வாழ்க்கை அறிவியல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மூலதனம் வாழ்க்கை அறிவியல் Today - Breaking & Trending Today

Nuvalent bags $135M to trial resistance-beating kinase inhibitors in lung cancer


May 11, 2021 7:00am
Nuvalent will use the money to fund clinical development of its parallel lead programs, NVL-520 and NVL-655. (Robina Weermeijer/Unsplash)
Nuvalent has raised $135 million to take ROS1 and ALK kinase inhibitors into the clinic. The series B, which comes months after Nuvalent disclosed a $50 million round, sets Nuvalent up to study drugs designed to improve on products such as Roche’s Alecensa and Pfizer’s Xalkori.
Kinase inhibitors have improved cancer outcomes by binding to enzymes that drive the proliferation, survival and metastasis of tumors. However, changes to the binding sites lead to resistance, creating a need for treatments that are effective in patients who stop responding to existing drugs. Nuvalent is working to deliver those treatments. ....

United States , Roche Alecensa , Bain Capital Life Sciences , Capital Life Sciences , Fidelity Management , Deerfield Management , Point Therapeutic , ஒன்றுபட்டது மாநிலங்களில் , பைன் மூலதனம் வாழ்க்கை அறிவியல் , மூலதனம் வாழ்க்கை அறிவியல் , நம்பகத்தன்மை மேலாண்மை , தீர்ப்பியல்ட் மேலாண்மை ,